Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
PR Newswire•07/10/2026•07:03 ET
0
Key Highlights
- ➤175+ biotechs adopted pre-configured Veeva Basics applications
- ➤Veeva Basics applications launch in weeks and scale through commercialization
- ➤Structure Therapeutics insourced submission publishing, improving quality control and regulatory timelines
- ➤Veeva Basics unifies clinical, regulatory, quality, medical, and commercial applications
Expert Statements
Bryan Ball, Chief technology operations officer at Whitehawk Therapeutics
“As a growing company with under 40 employees, we're focused on developing science fast to deliver antibody-drug conjugates (ADCs) that target difficult-to-treat cancers.”
Bryan Ball, Chief technology operations officer at Whitehawk Therapeutics
“Our partnership with Veeva helped us replace paper processes with industry-leading solutions without an IT team or complex customizations. Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance.”
Darryl Clarke, Global head, regulatory operations at Structure Therapeutics
“Insourcing our submission publishing through Veeva Basics gave us sharper quality control and significantly faster regulatory timelines.”
Darryl Clarke, Global head, regulatory operations at Structure Therapeutics
“We have modern applications with global support to execute quickly now, and the flexibility to scale in the future.”
Jim Thai, Vice president, Veeva Basics
“Biotechs are responsible for so much of the innovation shaping the industry and they need technology that reflects the pace that they operate in.”
Jim Thai, Vice president, Veeva Basics
“It's been a privilege to work with industry pioneers and build this community of Veeva Basics customers advancing drug development.”
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development PR Newswire
More than 175 biotechs use pre-configured applications to streamline operations
Get started
Create a free account to read the full story.